For instance, while DNA damaging agents, such as a number of chemotherapeutic drugs employed for treatment of patients with different types of cancer, are able to ignite antitumor immune responses through the upregulation of immunostimulatory stress-regulated molecules (e.g. NKG2D ligands), the same agents can also increase the expression of immunosuppressive axis, including certain inhibitory immune checkpoints, hence favouring cancer immunoevasion. Here, KLRK1 is linked to cancer.